{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:22:09Z","timestamp":1780611729377,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.urolonc.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T08:15:49Z","timestamp":1496391349000},"page":"492-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimizing management of upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Matthew T.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.05.009_bib1","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.05.009_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib3","first-page":"816","article-title":"Now is the time for perioperative chemotherapy in upper tract urothelial cancer","volume":"35","author":"Siefker-Radtke","year":"2017"},{"key":"10.1016\/j.urolonc.2017.05.009_bib4","first-page":"7","article-title":"Cancer Statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2017.05.009_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0090-4295(97)00230-6","article-title":"Upper-tract transitional cell carcinoma","volume":"50","author":"Tawfiek","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.05.009_bib6","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1464-410X.2009.08838.x","article-title":"Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract","volume":"104","author":"Colin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.05.009_bib8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ki.2011.371","article-title":"Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid","volume":"81","author":"Jelakovic","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.urolonc.2017.05.009_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.MP.0000024263.25043.0C","article-title":"Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis","volume":"15","author":"Blaszyk","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib10","first-page":"6796","article-title":"Frequent microsatellite instability in sporadic tumors of the upper urinary tract","volume":"62","author":"Hartmann","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2017.05.009_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","article-title":"Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy","volume":"112","author":"Xylinas","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.05.009_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","article-title":"Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma","volume":"109","author":"Favaretto","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.05.009_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.urolonc.2011.07.011","article-title":"Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma","volume":"31","author":"Messer","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.urolonc.2014.02.018","article-title":"Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract","volume":"32","author":"Chung","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.05.009_bib17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.ejso.2014.06.007","article-title":"Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies","volume":"40","author":"Yakoubi","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European guidelines on upper tract urothelial carcinomas: 2015 update","volume":"68","author":"Roupr\u00eat","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib20","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","article-title":"Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)","volume":"60","author":"O\u2019Brien","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.05.009_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.05.009_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer","volume":"29","author":"Porter","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","article-title":"Urothelial carcinoma management in elderly or unfit patients","volume":"14","author":"Bellmunt","year":"2016","journal-title":"EJC Suppl"},{"key":"10.1016\/j.urolonc.2017.05.009_bib29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.05.009_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.05.009_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.urology.2004.04.024","article-title":"Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group","volume":"64","author":"Linardou","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.05.009_bib33","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2015.12.007","article-title":"Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study","volume":"89","author":"Siefker-Radtke","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.05.009_bib35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2017.05.009_bib36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.urolonc.2017.05.009_bib39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.05.009_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with differerent sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2017.05.009_bib41","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2017.05.009_bib42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2017.05.009_bib43","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.05.009_bib44","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.urolonc.2017.05.009_bib46","doi-asserted-by":"crossref","first-page":"e0137141","DOI":"10.1371\/journal.pone.0137141","article-title":"Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison","volume":"10","author":"Sanford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.05.009_bib47","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1016\/j.juro.2017.02.2257","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC)","volume":"197","author":"Moss","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw373.14","article-title":"Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates","author":"Kilgore","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2017.05.009_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw373.09","article-title":"Safety and activity of the pan\u2013fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma","author":"Soria","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:11:25Z","timestamp":1761041485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917302193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1078143917302193"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing management of upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}